PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
January 14, 2026Journal of Clinical Oncology

Molecular profiling and potential therapeutic implications of molecular testing utilizing a large database of hepatocellular carcinoma patients.

View Full Paper
Ask AI
Bookmark
Share

Authors

AHAlexander HaydenVAVida AlamiJHJunxiao Hu

Discussion

Loading...

Member takes

Overview

Molecular profiling reveals genetic alterations in hepatocellular carcinoma, suggesting potential for targeted therapies and ongoing clinical trials.

Key Points

  • This research aims to identify genetic alterations in hepatocellular carcinoma patients and their implications for targeted therapies.
  • Utilized the Clinico-Genomic Database to analyze molecular testing results from 447 HCC patients.
  • Evaluated frequency of genetic alterations, excluding those present in less than 1% of patients.
  • Performed univariate analysis using Fischer’s exact test to correlate alterations with HCC risk factors.
  • Identified FDA approved targeted therapies linked to found alterations and current clinical trials evaluating new therapies.
  • Analyzed molecular data revealed 56 alterations present in over 1% of HCC patients.
  • Key altered genes included TERT, CTNNB1, TP53, ARID1A, and FGF19.
  • 10 of 56 alterations have associated FDA approved therapies; 5 alterations are under investigation in clinical trials.

Cite This Study

Hayden et al. (2026) studied this question.

synapsesocial.com/papers/6966f2fb13bf7a6f02c006e8https://doi.org/10.1200/jco.2026.44.2_suppl.594
View Full Paper
Ask AI
Bookmark
Share